Cardiovascular – Other therapeutic responses

Sanofi-aventis continues to market a number of classic cardiovascular products in many parts of the world.

Lasilix® (furosemide) is still a diuretic treatment of reference. With sales of over 60 million packs a year, it is one of the Group’s best-selling products by volume. 35 years after it was first marketed, Cordarone® (amiodarone®) is still an anti-arrhythmic of choice, enjoying steady growth worldwide.

Tildiem® (diltazem), used in the treatment of angina and hypertension, is marketed in 54 countries in Europe, Asia, Africa, the Middle East and Latin America. Antihypertensive Selectol® (celiprolol), cholesterol-lowering Lipanor® (ciprofibrate) and anti-angina medicine Ikorel® (nicorandil) are also successfully marketed in a number of European countries.